Leuplin Gains Two Additional Indications
Takeda Chemical's Leuplin (leuprorelin acetate) has gained two additional indications in Japan for endometriosis and precocious puberty.
The product became available first in the USA for prostate cancer in 1985 and is currently marketed for this indication or endometriosis in 34 countries. The New Drug Applications for the indications were filed in July 1992. In Japan, the product is also in Phase III trials for uterine fibroids and Phase II for breast cancer.
Also in Takeda's pipeline, according to Pharma Japan, are filed NDAs for AO-128 for diabetes (filed in December 1991), the antibiotic cefozopran, (filed December 1992) and AA-2414 for bronchial asthma (filed in October 1993).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze